A majority of low (1-10%) er positive breast cancers behave like hormone receptor negative tumors

Journal of Cancer

Volumn 5, Issue 2, 2014, Pages 156-165

  Prabhu, Jyothi S ^a   Korlimarla, Aruna ^a   Desai, Krisha ^a   Alexander, Annie ^a   Raghavan, Rohini ^a   Anupama, C E ^a   Dendukuri, Nandini ^b   Manjunath, Suraj ^a   Correa, Marjorrie ^a   Raman, N ^c   Kalamdani, Anjali ^c   Prasad, M S N ^c   Gopinath, K S ^c   Srinath, B S ^d   Sridhar, T S ^a  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^b MCGILL UNIVERSITY   (Canada)

^c Rangadore Memorial Hospital   (India)

^d Sri Shankara Cancer Hospital and Research Centre   (India)

Author keywords

Breast cancer; Er 1 10 ; FFPE; Gene expression; Q RT PCR

Indexed keywords

ANTHRACYCLINE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SPECIFIC SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR BIOLOGY; MULTICENTER STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROBABILITY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; VERY ELDERLY;

EID: 84893549118     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7668     Document Type: Article

References (35)

1. Desombre ER, Smith S, Block GE, et al. Prediction of breast cancer response to endocrine therapy. Cancer chemotherapy reports Part 1. 1974; 58: 513-9.
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005; 365: 1687-717. doi:10.1016/s0140-6736(05)66544-0.
3. Allred DC, Bustamante MA, Daniel CO, et al. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Archives of surgery (Chicago, Ill: 1960). 1990; 125: 107-13.
4. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. International journal of cancer Journal international du cancer. 2000; 89: 111-7.
5. Badve S, Vladislav IT, Spaulding B, et al. EP1: a novel rabbit monoclonal antibody for detection of oestrogen receptor alpha. Journal of clinical pathology. 2013. doi:10.1136/jclinpath-2012-201391.
6. Kim C, Tang G, Pogue-Geile KL, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29: 4160-7. doi:10.1200/jco.2010.32.9615.
7. Denkert C, Loibl S, Kronenwett R, et al. RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2013; 24: 632-9. doi:10.1093/annonc/mds339.
8. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17: 1474-81.
9. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28: 2784-95. doi:10.1200/JCO.2009.25.6529.
10. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-52. doi:10.1038/35021093.
11. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer research. 2001; 61: 5979-84.
12. Schneider J, Ruschhaupt M, Buness A, et al. Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. International journal of cancer Journal international du cancer. 2006; 119: 2974-9. doi:10.1002/ijc.22234.
13. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13: 4415-21. doi:10.1158/1078-0432.CCR-07-0122.
14. Symmans WF, Hatzis C, Sotiriou C, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28: 4111-9. doi:10.1200/JCO.2010.28.4273.
15. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530-6. doi:10.1038/415530a.
16. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England journal of medicine. 2004; 351: 2817-26. doi:10.1056/NEJMoa041588.
17. Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26: 2473-81. doi:10.1200/JCO.2007.13.6424.
18. Harbeck N, Rody A. Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30: 686-9. doi:10.1200/jco.2011.38.9619.
19. Wolff AC, Dowsett M. Estrogen receptor: a never ending story? Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29: 2955-8. doi:10.1200/jco.2011.35.4589.
20. Iwamoto T, Booser D, Valero V, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30: 729-34. doi:10.1200/JCO.2011.36.2574.
21. Deyarmin B, Kane JL, Valente AL, et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Annals of surgical oncology. 2013; 20: 87-93. doi:10.1245/s10434-012-2588-8.
22. Desai SB, Moonim MT, Gill AK, et al. Hormone receptor status of breast cancer in India: a study of 798 tumours. Breast. 2000; 9: 267-70; discussion 70. doi:10.1054/brst.2000.0134.
23. Green M, Raina V. Epidemiology, screening and diagnosis of breast cancer in the Asia-Pacific region: Current perspectives and important considerations. Asia-Pacific Journal of Clinical Oncology. 2008; 4: S5-S13. doi:10.1111/j.1743-7563.2008.00191.x.
24. Shet T, Agrawal A, Nadkarni M, et al. Hormone receptors over the last 8 years in a cancer referral center in India: What was and what is? Indian Journal of Pathology and Microbiology. 2009; 52: 171. doi:10.4103/0377-4929.48909.
25. Dey S, Boffetta P, Mathews A, et al. Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. International journal of cancer Journal international du cancer. 2009; 125: 1663-70. doi:10.1002/ijc.24460.
26. Manjunath S, Prabhu JS, Kaluve R, et al. Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype? Indian journal of surgical oncology. 2011; 2: 122-5. doi:10.1007/s13193-011-0072-8.
27. Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries? World journal of surgery. 2010; 34: 2308-24. doi:10.1007/s00268-010-0683-1.
28. Korlimarla A, Prabhu JS, Anupama CE et al. Separate Quality-Control Measures Are Necessary for Estimation of RNA and Methylated DNA from Formalin-Fixed, Paraffin-Embedded Specimens by Quantitative PCR. The Journal of molecular diagnostics: 2014; In press.
29. Prabhu JS, Wahi K, Korlimarla A, et al. The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012; 33: 315-23. doi:10.1007/s13277-012-0343-1.
30. Ghosh J, Gupta S, Desai S, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian journal of cancer. 2011; 48: 391-6. doi:10.4103/0019-509X.92245.
31. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001; 19: 980-91.
32. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98: 10869-74. doi:10.1073/pnas.191367098.
33. Allred DC.Problems and solutions in the evaluation of hormone receptors in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26: 2433-5. doi:10.1200/JCO.2007.15.7800.
34. Hoch RV, Thompson DA, Baker RJ, et al. GATA-3 is expressed in association with estrogen receptor in breast cancer. International journal of cancer Journal international du cancer. 1999; 84: 122-8.
35. Skrondal A, Rabe-Hesketh S. Generalized latent variable modeling. Multilevel, longitudinal, and structural equation models. CRC Press; 2004.